Herrmann Ken, Takei Toshiki, Kanegae Kakuko, Shiga Tohru, Buck Andreas K, Altomonte Jennifer, Schwaiger Markus, Schuster Tibor, Nishijima Kenichi, Kuge Yuji, Tamaki Nagara
Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan.
Mol Imaging Biol. 2009 Sep-Oct;11(5):356-63. doi: 10.1007/s11307-009-0205-4. Epub 2009 Apr 2.
The aim of this study was to assess the clinical value of [(11)C]methionine-PET (MET-PET) for detection and localization of parathyroid adenomas in patients without prior thyroidectomy.
A retrospective analysis of patients with suspected parathyroid adenomas undergoing imaging with MET-PET was performed. Prior thyroidectomy was an exclusion criterion. Forty-one patients with a total of 49 MET-PET scans were included. MET-PET consisted of whole-body images obtained 15-20 min after injection of 430 +/- 81 MBq of MET using a dedicated PET scanner. Imaging findings were validated by histology or other imaging studies and clinical follow-up on a lesion, side, and location basis. Comparison of PET results to other imaging modalities including ultrasound, MIBI scintigraphy, and morphological imaging [computed tomography (CT) and/or magnetic resonance imaging] and subgroup analysis of primary vs. secondary hyperparathyroidism was performed.
Twenty-three of 49 PET scans revealed pathologic findings, whereas 26 of 49 scans were negative. Validation of PET findings for detection and localization of parathyroid adenomas resulted in an overall sensitivity of MET-PET of 54%, 49%, and 35% on a lesion, side, and location basis, respectively. Sensitivity of MET-PET was inferior compared to ultrasonography (50% vs. 93%), MIBI scintigraphy (53% vs. 74%) and morphological imaging (52% vs. 74%). Subgroup analysis revealed higher sensitivity for MET-PET in secondary HPT (sHPT) than primary HPT (pHPT; 62% vs. 43%; side basis).
In patients with initial diagnosis of hyperparathyroidism and no prior thyroidectomy, the sensitivity of MET-PET for detection and localization of parathyroid adenomas is markedly lower compared to previous reports. While performance was better in sHPT, we believe that MET-PET cannot be recommended for pHPT localization in this clinically relevant subcollective. The clinical value of MET/PET in patients with hyperparathyroidism should be further investigated in a prospective study utilizing anatometabolic imaging with a PET/CT device.
本研究旨在评估[(11)C]蛋氨酸 - 正电子发射断层扫描(MET - PET)在未接受过甲状腺切除术的患者中检测和定位甲状旁腺腺瘤的临床价值。
对疑似甲状旁腺腺瘤并接受MET - PET成像的患者进行回顾性分析。排除标准为既往有甲状腺切除术史。纳入41例患者,共进行了49次MET - PET扫描。MET - PET包括使用专用PET扫描仪在注射430±81 MBq的MET后15 - 20分钟获得的全身图像。通过组织学或其他影像学检查以及对病变、侧别和位置的临床随访来验证影像学结果。将PET结果与其他影像学检查方法进行比较,包括超声、MIBI闪烁扫描以及形态学成像[计算机断层扫描(CT)和/或磁共振成像],并对原发性与继发性甲状旁腺功能亢进进行亚组分析。
49次PET扫描中有23次显示病理性结果,而49次扫描中有26次为阴性。对PET结果用于检测和定位甲状旁腺腺瘤的验证显示,MET - PET在病变、侧别和位置基础上的总体敏感性分别为54%、49%和35%。MET - PET的敏感性低于超声检查(50%对93%)、MIBI闪烁扫描(53%对74%)和形态学成像(52%对74%)。亚组分析显示,MET - PET在继发性甲状旁腺功能亢进(sHPT)中的敏感性高于原发性甲状旁腺功能亢进(pHPT;侧别基础上为62%对43%)。
在初诊甲状旁腺功能亢进且未接受过甲状腺切除术的患者中,MET - PET检测和定位甲状旁腺腺瘤的敏感性明显低于既往报道。虽然在sHPT中表现较好,但我们认为在这个临床相关的亚组中,MET - PET不推荐用于pHPT的定位。甲状旁腺功能亢进患者中MET/PET的临床价值应在一项利用PET/CT设备进行解剖代谢成像前瞻性研究中进一步探讨。